Ogerin

Ogerin

SCHEMBL29407423

Nc1nc(NCc2ccccc2)nc(-c2ccccc2CO)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR68 Q15743 6/20 1.00
HTR2B P41595 4/20 1.00
ADORA2A P29274 2/20 1.00
NPSR1 Q6W5P4 1/20 0.63
HTR1A P08908 1/20 0.63
ACKR3 P25106 2/20 0.60
MTNR1A P48039 1/20 0.56
MTNR1B P49286 1/20 0.56
TPH1 P17752 5/20 0.51
CDK9 P50750 1/20 0.47
APP P05067 2/20 0.47
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390771 0.81 ADORA2A (0.66) GPR68HTR2BADORA2AACKR3TSHR
SCHEMBL6727019 0.77 NPSR1 (0.74) GPR68HTR2BADORA2ANPSR1HTR1A
SCHEMBL3301514 0.77 NPSR1 (0.74) GPR68HTR2BADORA2ANPSR1HTR1A
Hydrochloric Acid SCHEMBL9247173 0.76 NPSR1 (0.72) GPR68HTR2BADORA2ANPSR1HTR1A
SCHEMBL9566454 0.74 GPR68 (0.64) GPR68HTR2BADORA2ANPSR1HTR1A
SCHEMBL8413880 0.74 GPR68 (0.64) GPR68HTR2BADORA2ANPSR1HTR1A
SCHEMBL30206799 0.73 HTR2B (1.00) GPR68HTR2BADORA2ANPSR1HTR1A
SCHEMBL14869452 0.73 NPSR1 (0.59) GPR68HTR2BADORA2ANPSR1HTR1A
SCHEMBL4351104 0.71 NPSR1 (0.57) GPR68HTR2BADORA2ANPSR1HTR1A
SCHEMBL14869402 0.70 NPSR1 (0.64) GPR68HTR2BADORA2ANPSR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250345340-A1 METHODS FOR THE PREVENTION AND TREATEMENT OF POST-OPERATIVE ABDOMINAL ADHESIONS UNIVERSITY OF ROCHESTER (US) 2025-11-13 US claimed
WO-2023285878-A1 METHODS FOR DETECTING, TREATING, AND PREVENTING GPR68-MEDIATED OCULAR DISEASES, DISORDERS, AND CONDITIONS AVIATION-OPHTHALMOLOGY (SE) 2023-01-19 WO claimed
US-20250345340-A1 METHODS FOR THE PREVENTION AND TREATEMENT OF POST-OPERATIVE ABDOMINAL ADHESIONS UNIVERSITY OF ROCHESTER (US) 2025-11-13 US disclosed
US-20250345340-A1 METHODS FOR THE PREVENTION AND TREATEMENT OF POST-OPERATIVE ABDOMINAL ADHESIONS UNIVERSITY OF ROCHESTER (US) 2025-11-13 US disclosed
US-20250304585-A1 SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2025-10-02 US disclosed
EP-4540249-A1 SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS Yeda Research and Development Co. Ltd (IL) 2025-04-23 EP disclosed
US-20250099438-A1 SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS UNIVERSITY OF MARYLAND, BALTIMORE 2025-03-27 US disclosed
US-12194027-B2 Small molecule inhibitors of GPCR GPR68 and related receptors for treating cancer, glioblastoma, and other indications UNIVERSITY OF MARYLAND, BALTIMORE (US) 2025-01-14 US disclosed
US-20240327364-A1 THERAPEUTIC TARGETING OF GPR68 TO INDUCE FERROPTOSIS UNIVERSITY OF MARYLAND, BALTIMORE 2024-10-03 US disclosed
US-20240139326-A1 METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2024-05-02 US disclosed
WO-2023242845-A1 SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2023-12-21 WO disclosed
WO-2023285878-A1 METHODS FOR DETECTING, TREATING, AND PREVENTING GPR68-MEDIATED OCULAR DISEASES, DISORDERS, AND CONDITIONS AVIATION-OPHTHALMOLOGY (SE) 2023-01-19 WO disclosed
US-20220202785-A1 SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-30 US disclosed
EP-3955922-A1 SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS University of Maryland, Baltimore (US) 2022-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327364-A1 THERAPEUTIC TARGETING OF GPR68 TO INDUCE FERROPTOSIS GPR68, GPR65, GPR84 GPR68 1/4885HTR2B 4538/4885ADORA2A 777/4885
US-20250099438-A1 SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS GPR68, GPR65, GPR4 GPR68 1/4885HTR2B 864/4885ADORA2A 900/4885
US-20240139326-A1 METHACRYLAMIDES PROTEIN BINDERS AND USES THEREOF STAMBP, HSPBP1, ECPAS GPR68 3833/4885HTR2B 3777/4885ADORA2A 3929/4885
US-12194027-B2 Small molecule inhibitors of GPCR GPR68 and related receptors for treating cancer, glioblastoma, and other indications GPR68, GPR65, GPR4 GPR68 1/4885HTR2B 864/4885ADORA2A 900/4885
US-20250345340-A1 METHODS FOR THE PREVENTION AND TREATEMENT OF POST-OPERATIVE ABDOMINAL ADHESIONS GPR68, GPR65, GPR180 GPR68 1/4885HTR2B 2615/4885ADORA2A 514/4885
US-20250304585-A1 SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS CASR, NPSR1, GSR GPR68 1052/4885HTR2B 980/4885ADORA2A 1407/4885
US-20220202785-A1 SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS GPR68, GPR65, GPR4 GPR68 1/4885HTR2B 864/4885ADORA2A 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.